| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 4.4, positive 4.5, negative -0.1) on 20251114. The forces of Sentiment towards Fundamentals (2.2), Price Level (2), Valuation Sentiment (1.7), Option Speculation (1.5), Sector Price Trend (1.5), and Broad Market Trend (-0.1) will drive up the price. The forces of and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (4.5). The extreme bullish overall sentiment (4.4) may signal the top of this uptrend. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-14 | 3% | 1.1% | 151.87 | 96 | -0.59% | 0.54% | 2.9 | 1.5 | 2.2 | 1.2 |
| 2025-11-13 | 1% | 0.9% | 152.77 | 112 | -0.03% | 0.61% | 3.1 | 1.6 | 2.4 | -0.2 |
| 2025-11-12 | 1% | 1% | 152.81 | 126 | 1.4% | 0.55% | 3.5 | 1.6 | 2.2 | 2.2 |
| 2025-11-11 | 1% | 1.1% | 150.69 | 126 | 2.32% | 0.41% | 3.1 | 0.9 | 2.2 | 2.2 |
| 2025-11-10 | 1% | 1.4% | 147.28 | 93 | 0.79% | 0.07% | 2.9 | 0.6 | 2.1 | -1.9 |
| 2025-11-09 | 0% | 1.6% | 3.8 | 0.5 | 2.1 | 8 | ||||
| 2025-11-08 | 1% | 1.7% | 3.4 | 0.5 | 2.1 | 7 | ||||
| 2025-11-07 | 1% | 1.7% | 146.12 | 77 | 0.14% | 0% | 0.8 | 0.5 | 2.1 | -0.6 |
| 2025-11-06 | 2% | 1.9% | 145.92 | 76 | 0.19% | -0.07% | 0.4 | 0.3 | 1.8 | 2.4 |
| 2025-11-05 | 2% | 2% | 145.64 | 74 | 0.43% | 0% | 0.7 | 0.1 | 1.9 | 1.2 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (-4) FDA's plan to boost cheaper copycat drugs could stall at the patent office The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the opposite direction. (https://www.cbsnews.com/moneywatch/) Fri. Nov 14, 2025 | |
| 2 (8) Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump. (https://www.marketbeat.com/) Fri. Nov 14, 2025 | |
| 3 (7) Merck To Acquire Cidara For $221.50/shr Merck (MRK) and Cidara Therapeutics, Inc. (CDTX) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9. (https://www.rttnews.com/) Fri. Nov 14, 2025 | |
| 4 (6) Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate. (https://www.benzinga.com/) Fri. Nov 14, 2025 | |
| 5 (-4) ResMed Inc. stock falls Friday, underperforms market Shares of ResMed Inc. RMD slipped 3.03% to $244.46 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.05% to 6,734.11 and Dow Jones Industrial Average DJIA falling 0.65% to 47,147.48. This was the stock's second consecutive day of losses. (https://www.marketwatch.com/) Fri. Nov 14, 2025 | |
| 6 (-4) Stryker Corp. stock underperforms Friday when compared to competitors Shares of Stryker Corp. SYK slid 3.00% to $362.22 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.05% to 6,734.11 and Dow Jones Industrial Average DJIA falling 0.65% to 47,147.48. The stock's fall snapped a three-day winning streak. (https://www.marketwatch.com/) Fri. Nov 14, 2025 | |
| 7 (3) Purdue Pharma Gets Court Nod for Bankruptcy Exit, Sackler Deal Purdue Pharma LP won court approval to exit bankruptcy, capping six years of legal wrangling over a multibillion-dollar settlement and liability releases for the opioid manufacturer’s Sackler family owners. (https://www.bloomberg.com/) Fri. Nov 14, 2025 | |
| 8 (6) European Obesity Stocks Join Healthcare Rally as AI Trade Ebbs European weight-loss drug developers have staged something of a comeback this week, as investors rotate into healthcare from AI-exposed momentum stocks. (https://www.bloomberg.com/) Fri. Nov 14, 2025 | |
| 9 (8) Kura Scores A Big Win As FDA Approves Its New Leukemia Pill Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price target to $38. (https://www.benzinga.com/) Fri. Nov 14, 2025 | |
| 10 (-4) Virgin Galactic misses on Q3 revenue, Bristol Myers halts drug trial Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Virgin Galactic (SPCE) shares rising while missing third quarter revenue estimates and narrowing its net losses below forecasts, Applied Materials (AMAT) forecasting a drop in chip equipment sales, and Bristol Myers Squibb (BMY) halting its trial for a blood clot drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Fri. Nov 14, 2025 | |
| 11 (6) Merck to buy Cidara for $9.2B, Netflix nears 10-for-1 stock split Yahoo Finance host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute, including tech names Nvidia (NVDA), Tesla (TSLA), and Broadcom (AVGO) in recovery mode from Thursday's tech sell-off, Merck's (MRK) plans to buy Cidara Therapeutics (CDTX) in a deal worth up to $9.2 billion, and Netflix (NFLX) prepares to execute its 10-for-1 stock split. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. (https://finance.yahoo.com/) Fri. Nov 14, 2025 | |
| 12 (3) This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil. (https://www.marketwatch.com/) Fri. Nov 14, 2025 | |
| 13 (4) Novo Nordisk's shareholders approve chaotic board overhaul as weight loss market challenges loom Novo Nordisk shareholders approved the proposals to revamp the board with 93% voting in favor. The foundation controls over 75% of votes. (https://www.cnbc.com/) Fri. Nov 14, 2025 | |
| 14 (-2) Ozempic Maker Novo Nordisk Faces Board Shakeup Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market. (https://www.benzinga.com/) Fri. Nov 14, 2025 | |
| 15 (-7) Goldman Sachs, UnitedHealth share losses lead Dow's nearly 525-point fall Dragged down by losses for shares of Goldman Sachs and UnitedHealth, the Dow Jones Industrial Average is in a selloff Friday morning. The Dow Dow Jones Industrial Average was most recently trading 523 points lower (-1.1%), as shares of Goldman Sachs Goldman Sachs Group Inc. and UnitedHealth UnitedHealth Group Inc. have contributed to the index's intraday decline. (https://www.marketwatch.com/) Fri. Nov 14, 2025 | |
| 16 (-6) UnitedHealth, Nike share losses lead Dow's 300-point drop Shares of UnitedHealth and Nike are retreating Friday morning, dragging the Dow Jones Industrial Average into negative territory. Shares of UnitedHealth UnitedHealth Group Inc. and Nike Nike Inc. Cl B have contributed to the blue-chip gauge's intraday decline, as the Dow Dow Jones Industrial Average was most recently trading 303 points (0.6%) lower. (https://www.marketwatch.com/) Fri. Nov 14, 2025 | |
| 17 (-6) Botox Rivals Are Coming for AbbVie’s Crown Jewel Cheaper alternatives threaten its $2.7 billion treatment. (https://www.bloomberg.com/) Fri. Nov 14, 2025 | |
| 18 (7) Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention. (https://www.cnbc.com/) Fri. Nov 14, 2025 | |
| 19 (-5) Hapvida Owners Boost Stakes After Earnings Miss Triggers Rout The controlling shareholders of Brazil’s Hapvida Participacoes e Investimentos SA are increasing their stakes in the health care operator after disappointing earnings triggered the company’s worst selloff since it went public in 2018. (https://www.bloomberg.com/) Thu. Nov 13, 2025 | |
| 20 (8) Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major market. (https://finance.yahoo.com/) Thu. Nov 13, 2025 | |
| 21 (-2) Money Moving Into Healthcare Not AI; Four Fed Presidents Do Not Want a Rate Cut; Euphoria Wearing Off Rotating To Healthcare Please click here for an enlarged chart comparing Invesco QQQ Trust Series 1 (NASDAQ: (https://www.benzinga.com/) Thu. Nov 13, 2025 | |
| 22 (-2) Elevance Seeks to Keep NYC Contract in Secretive Legal Fight Elevance Health Inc. is trying to keep a major contract to provide health benefits for New York City public employees by arguing the city was “arbitrary and capricious” when it gave the lucrative award to its rivals. (https://www.bloomberg.com/) Thu. Nov 13, 2025 | |
| 23 (-2) The Fight to Save the $2.7 Billion Botox Empire Competition and the “natural look” have created a perfect storm. (https://www.bloomberg.com/) Thu. Nov 13, 2025 | |
| 24 (2) Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal AFPs promise to connect patients with more-affordable options for accessing specialty medications that often come at very high costs. There's a major catch. (https://www.cnbc.com/) Thu. Nov 13, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA